期刊文献+

肿瘤分子流行病学与肿瘤标志物 被引量:2

Cancer molecular epidemiology and tumor markers
下载PDF
导出
摘要 肿瘤分子流行病学应用流行病学方法研究肿瘤标志物在高危人群和癌症患者中的分布和影响因素,对机体致癌物质暴露、生物学效应以及个体遗传易感性进行测量和评价,试图打开肿瘤病因"黑箱",揭示肿瘤发病的本质,它对肿瘤标志物的研究涉及病因学、预防医学和临床治疗各个领域。肿瘤分子流行病学要严格设计和实施,用质量控制原则、循证医学原则和伦理学原则指导肿瘤标志物的研究和应用。随着蛋白质组学等新兴学科的加入,结合了多学科优势的肿瘤分子流行病学正在迅速发展之中。 Cancer molecular epidemiology focus on distribution and pathogenesis of tumor markers in high-risk populations and cancer patients. Cancer molecular epidemiology tries to open the "black box" and to elucidate the nature of cancer through the measurement and evaluation of exposure and response to carcinogens and individual genetic susceptibility, involving the fields of etiology, preventive medicine and clinical medicine. We need rigorously strengthen the design and implementation of cancer molecular epidemiology, the research and application of TM should enhance the principles of quality, evidence and ethics. With the utility of new subject tools such as proteomics, cancer molecular epidemiology which combines the advantages of multi-subjects is now quickly changing.
作者 李文庆 张联
出处 《基础医学与临床》 CSCD 北大核心 2007年第7期729-738,共10页 Basic and Clinical Medicine
关键词 肿瘤分子流行病学 肿瘤标志物 cancer molecular epidemiology tumor markers
  • 相关文献

参考文献70

  • 1McMichael AJ. Invited commentary -“ Molecular Epidemiology” : New pathway or new travelling companion? [ J]. Am J Epidemiol, 1994, 140:1 - 11.
  • 2Perera FP, Weistein lB. Molecular epidemiology : recent advances and future directions [J]. Carcinogenesis, 2000, 21 : 517 - 524.
  • 3Schrohl AS, Holten-Andersen M, Sweep F, et al. Tumor markers: From laboratory to clinical utility [ J ]. Mol Cell Proteomics, 2003, 2:378 - 387.
  • 4Diamandis EP, Fritsche H, Chan D, et al. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications [ M ]. Washington DC : AACC Press, 2002 : 3 --8.
  • 5Merlo DF, Sormani MP, Bruzzi P. Molecular epidemiology: New rules for new tools ? [ J ]. Mutat Res, 2006, 600:3 -11.
  • 6Perara FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation [ J]. J Chronic Dis, 1982, 35: 581 -600.
  • 7Sturgeon C. Practice guidelines for tumor marker use in the clinic [J]. Clin Chem, 2002, 48:1151 -1159.
  • 8McGuire WL. Breast cancer prognostic factors: Evaluation guidelines [J]. J Nat Cancer Inst, 1991, 83: 154- 155.
  • 9Wu JT. Circulating tumor markers of the new millennium. Target therapy, early detection, and prognosis [ J ]. Clin Chem, 2003, 49:711 -712.
  • 10Chen Ru, Pan Sheng, Brentnall TA, et al. Proteomic profiling of pancreatic cancer for biomarker discovery [ J ]. Mol Cell Proteomics, 2005, 4:523 - 533.

二级参考文献17

  • 1唐金陵.循证医学: 循证医疗卫生决策[M].北京:北京大学医学出版社,2004..
  • 2唐金陵 见: 李立明 主编.循证医学[A].见: 李立明,主编.流行病学.第5版[C].北京: 人民卫生出版社,2003.367-377.
  • 3Evidence-Based Medicine Working Group. Evidence-based medicine: the new approach to teaching the practice of medicine. JAMA, 1992, 268: 2420-2425.
  • 4Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996, 312: 71-72.
  • 5Sackett DL, Straus SE, Richardson WS, eds. Evidence-based: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone, 2000.
  • 6Feinstein AR. Clinical epidemiology: the architecture of clinical Research. Philadelphia WB: Saunders Co, 1985.
  • 7Rothman KJ, Greenland S,eds. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1998.
  • 8Hulley SB, Cummings SR, Browner WS,eds. Designing clinical research: an epidemiologic approach. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
  • 9Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? BMJ, 2004,328: 514-517.
  • 10Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ, 1979, 121: 1193-1254 .

共引文献39

同被引文献20

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部